- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Avoiding Commercialization Pitfalls for CGTs
Lung-I Cheng, vice president of cell and gene therapy (CGT), Cencora (formerly AmerisourceBergen), discusses CGT commercialization strategies, common knowledge gaps, and what he wishes companies knew about commercialization strategies.
Commercialization is a tough road to navigate even for the most established bio/pharmaceutical therapies. But as cell and gene therapies (CGTs) continue to form roots and make a splash worldwide—but specifically in the US—commercialization forms its own version of standardization and best practices.
In this exclusive interview with Pharmaceutical Executive, Lung-I Cheng, vice president of CGT,Cencora(formerly AmerisourceBergen), discusses:
- Defining CGT commercialization strategies and foundational knowledge—and the best music metaphor
- What he wishes companies knew about commercialization strategies
- Common knowledge gaps of CGTs
- How CGT developers can overcome key challenges, including those related to patient access, regulatory requirements, and market access
- How planning for allogeneic cell therapies differs from autologous cell therapies and gene therapies
- How companies can demonstrate CGT value as more products enter the development pipeline (and competition intensifies)
- When to start planning a CGT commercialization strategy
- Predictions for the CGT market in five years
About the speaker
Lung-I Cheng, PhD, is a vice president and head of Cencora’s CGT service line. He is responsible for advancing Cencora’s CGT strategy with a focus on expanding the company’s portfolio of services to better support CGT innovators throughout the product development and commercialization journey. Prior to joining Cencora(formerly AmerisourceBergen) in May 2022, he spent a decade in biopharma—most recently serving as the head of global value and access for cell therapies, pipeline, and business development at Takeda.
About the Pharm Exec Podcast
The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
